CY1117910T1 - Σχημα δοσολογιας αλλαντικης τοξινης για προφυλαξη εναντι χρονιας ημικρανιας - Google Patents

Σχημα δοσολογιας αλλαντικης τοξινης για προφυλαξη εναντι χρονιας ημικρανιας

Info

Publication number
CY1117910T1
CY1117910T1 CY20161100813T CY161100813T CY1117910T1 CY 1117910 T1 CY1117910 T1 CY 1117910T1 CY 20161100813 T CY20161100813 T CY 20161100813T CY 161100813 T CY161100813 T CY 161100813T CY 1117910 T1 CY1117910 T1 CY 1117910T1
Authority
CY
Cyprus
Prior art keywords
dose
fixed
allant
preventive
years
Prior art date
Application number
CY20161100813T
Other languages
English (en)
Inventor
Catherine C Turkel
Sheena K Aurora
David W Dodick
Mitchell F Brin
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of CY1117910T1 publication Critical patent/CY1117910T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Διαταραχές όπως κεφαλαλγίες είναι δυνατόν να υποβληθούν σε αγωγή δια της χορήγησης αλλαντικής τοξίνης σε έναν ασθενή, ο οποίος υποφέρει από αυτές, όπως από μία κεφαλαλγία ημικρανίας. Αποκαλύπτεται ένα παράδειγμα συνδυασμού μίας σταθερής θέσης/σταθερής δόσης και μίας ενδεχόμενης σύμφωνα προς το σχήμα ακολούθα-τον-πόνο μεταβλητής δοσολογίας και θέσης έγχυσης για τη βελτιστοποίηση της κλινικής αποτελεσματικότητας της χορήγησης αλλαντικής τοξίνης για ασθενείς οι οποίοι υποφέρουν από χρόνια ημικρανία. Το πρόγραμμα έγχυσης απαιτεί μία ελάχιστη δόση 155 U με τη χρήση ενός σχήματος έγχυσης σταθερής θέσης, σταθερής δόσης σε 31-39 θέσεις σε 7 μυς κεφαλής/αυχένα, δηλαδή τον μετωπιαίο, επισπαστήρα, πυραμιδοειδή, ινιακό, κροταφίτη, τραπεζοειδή και τραχηλικό παρασπονδυλικό μυ.
CY20161100813T 2010-03-30 2016-08-17 Σχημα δοσολογιας αλλαντικης τοξινης για προφυλαξη εναντι χρονιας ημικρανιας CY1117910T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31923010P 2010-03-30 2010-03-30
US32066710P 2010-04-02 2010-04-02
PCT/US2011/030370 WO2011123456A1 (en) 2010-03-30 2011-03-29 Botulinum toxin dosage regimen for chronic migraine prophylaxis

Publications (1)

Publication Number Publication Date
CY1117910T1 true CY1117910T1 (el) 2017-05-17

Family

ID=44169214

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100813T CY1117910T1 (el) 2010-03-30 2016-08-17 Σχημα δοσολογιας αλλαντικης τοξινης για προφυλαξη εναντι χρονιας ημικρανιας

Country Status (23)

Country Link
US (9) US20100266638A1 (el)
EP (4) EP3311831A1 (el)
JP (4) JP5700874B2 (el)
KR (2) KR101786040B1 (el)
CN (1) CN102917728A (el)
AU (1) AU2011211375B2 (el)
BR (1) BR112012024920B1 (el)
CA (2) CA3019983A1 (el)
CY (1) CY1117910T1 (el)
DK (1) DK2552475T3 (el)
ES (1) ES2587437T3 (el)
HK (1) HK1179875A1 (el)
HU (1) HUE030094T2 (el)
IL (2) IL222192A (el)
MX (2) MX356204B (el)
MY (1) MY156827A (el)
NZ (2) NZ602983A (el)
PL (1) PL2552475T3 (el)
PT (1) PT2552475T (el)
RU (1) RU2549981C9 (el)
SG (1) SG184339A1 (el)
SI (1) SI2552475T1 (el)
WO (1) WO2011123456A1 (el)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US7758872B1 (en) * 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US9687186B2 (en) 2005-07-21 2017-06-27 Steadymed Ltd. Drug delivery device
IL175460A (en) 2006-05-07 2011-05-31 Doron Aurbach Drug delivery device
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
CN101918021A (zh) * 2007-10-23 2010-12-15 阿勒根公司 使用经修饰的梭菌毒素治疗泌尿生殖系统神经疾病的方法
US8617571B2 (en) * 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
SG172812A1 (en) 2008-12-31 2011-08-29 Revance Therapeutics Inc Injectable botulinum toxin formulations
KR102328155B1 (ko) 2009-06-25 2021-11-17 레반스 테라퓨틱스, 아이엔씨. 알부민­불포함 보툴리눔 독소 제제
US9125907B2 (en) * 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
JP2013541976A (ja) 2010-09-27 2013-11-21 ステディメッド， エルティーディー． サイズ効率的な薬物送達デバイス
US20120251574A1 (en) * 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US10111938B2 (en) * 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
WO2012174123A1 (en) * 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
EP2825225B1 (en) * 2012-03-15 2018-05-09 Steadymed Ltd. Enhanced infusion-site pain-reduction for drug-delivery devices
ES2715311T3 (es) 2012-03-19 2019-06-03 Steadymed Ltd Mecanismo de conexión de fluido para bombas tipo parche
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
AU2013246882B2 (en) 2012-04-13 2017-10-19 Lubrizol Advanced Materials, Inc. Compounds which inhibit neuronal exocytosis (II)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
WO2014078724A1 (en) 2012-11-16 2014-05-22 Finzi Eric Treatment of post-traumatic stress disorder using botulinum toxin a
KR20150135425A (ko) 2013-03-22 2015-12-02 리포텍 에스.에이. 피부, 점막 및/또는 손톱의 치료 및/또는 관리를 위한 세포외 다당류
EP3046470B1 (en) * 2013-09-20 2022-02-23 MDDT Inc. Diagnosing and treating movement disorders
US9480731B2 (en) * 2013-12-12 2016-11-01 Medy-Tox, Inc. Long lasting effect of new botulinum toxin formulations
EP3156412B1 (en) * 2014-05-29 2020-01-08 Procell Therapeutics Inc. Novel cell penetrating peptide, conjugate thereof with botulinum toxin, and use thereof
WO2015188945A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
EP3294305A4 (en) * 2015-05-15 2019-02-13 Carilion Clinic SYRINGES AND METHOD FOR USE THEREOF FOR THE TREATMENT OF BLADDER HYPERACTIVITY
US10463847B2 (en) 2015-06-11 2019-11-05 Steadymed Ltd. Infusion set
KR20180093983A (ko) * 2015-12-11 2018-08-22 레반스 테라퓨틱스, 아이엔씨. 신경전달물질을 사용한 기분 및 정서의 일차적 질환을 위한 보툴리눔 톡신
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
US20200023044A1 (en) * 2017-03-22 2020-01-23 Bonti, Inc. Botulinum neurotoxins for treating traumatic injuries
IT201800001119A1 (it) * 2018-01-16 2019-07-16 Francesco Giuseppe Bono Metodo regionalizzato e focalizzato di somministrazione di tossina botulinica mediante iniezione intradermica- subdermica-sottocutanea per il trattamento dell’emicrania cronica intrattabile e della cefalea
WO2020008402A2 (en) * 2018-07-05 2020-01-09 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives
WO2020146333A1 (en) 2019-01-07 2020-07-16 Azizzadeh Babak Treatment of stress disorders, including post-traumatic stress disorder, using acetylcholine release inhibiting neurotoxic proteins to reduce stress levels
AU2020340428A1 (en) * 2019-08-30 2022-03-03 AEON Biopharma, Inc. Neurotoxin compositions for use in treating headache
AU2021240083A1 (en) * 2020-03-18 2022-10-20 Revance Therapeutics, Inc. Injectable botulinum toxin methods for treating headaches
RU2763476C1 (ru) * 2021-01-13 2021-12-29 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Способ лечения мигрени
WO2023075060A1 (ko) * 2021-10-25 2023-05-04 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA962933A (en) 1969-12-05 1975-02-18 Yutaka Hori Metal foil-plastic laminated film and method of producing the same
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE292977T1 (de) 1994-05-09 2005-04-15 William J Binder Präsynaptische neurotoxine gegen migränekopfschmerzen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
MXPA01004254A (es) * 1998-10-27 2002-04-24 Mayo Foundation Metodos para intensificar la curacion de heridas.
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US20030118598A1 (en) 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
PT1253932E (pt) 2000-02-08 2005-07-29 Allergan Inc Composicoes farmaceuticas de toxina botulinica
US7780967B2 (en) 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US20010036943A1 (en) * 2000-04-07 2001-11-01 Coe Jotham W. Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6787517B1 (en) * 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
AU2002355730B2 (en) 2001-07-27 2007-09-13 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US6623742B2 (en) * 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
DE10150415A1 (de) * 2001-10-11 2003-05-15 Andres O Ceballos-Baumann Arzneimittel zur Prophylaxe und Therapie von Depressionen
US7077610B2 (en) 2002-02-07 2006-07-18 Buern Usa, L.L.C. Toggle bolt device
AU2003212473A1 (en) * 2002-03-01 2003-09-16 Solstice Neurosciences, Inc. Methods of treating nerve entrapment syndromes
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
CA2501856A1 (en) 2002-10-15 2004-04-29 Allergan, Inc. Botulinum toxin dental therapies and procedures
US7758872B1 (en) 2003-02-07 2010-07-20 Eric Finzi Method of treating depression
MXPA05009425A (es) 2003-03-06 2006-02-10 Botulinum Toxin Res Ass Inc Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica.
US7393537B2 (en) * 2003-04-25 2008-07-01 Allergan, Inc. Botulinum toxin for treatment of obsessive compulsive finger biting disorder
US6838434B2 (en) * 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US8609112B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8609113B2 (en) 2003-10-29 2013-12-17 Allergan, Inc. Botulinum toxin treatments of depression
US8617572B2 (en) 2003-10-29 2013-12-31 Allergan, Inc. Botulinum toxin treatments of depression
US8734810B2 (en) 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
US8048423B2 (en) * 2003-12-09 2011-11-01 Allergan, Inc. Botulinum toxin therapy for skin disorders
US7270287B2 (en) * 2004-01-06 2007-09-18 Allergan, Inc. Botulinum toxin treatment for kinesia
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US7299081B2 (en) * 2004-06-15 2007-11-20 Abbott Laboratories Analyte test device
CA2799413A1 (en) 2004-07-26 2006-02-23 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin
US7897147B2 (en) 2004-10-20 2011-03-01 Allergan, Inc. Treatment of premenstrual disorders
JP4994241B2 (ja) * 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
WO2006078588A2 (en) * 2005-01-18 2006-07-27 Allergan, Inc. Improved methods for treating headache
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US20150258183A1 (en) * 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
US8926991B2 (en) * 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US20090317377A1 (en) 2005-08-26 2009-12-24 Yeomans David C Therapy procedure for drug delivery for trigeminal pain
US7824694B2 (en) 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
US20080021437A1 (en) 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US9061025B2 (en) * 2006-08-31 2015-06-23 Allergan, Inc. Methods for selecting headache patients responsive to botulinum toxin therapy
RU2007104969A (ru) * 2007-02-09 2008-08-20 Маргарита Алексеевна Морозова (RU) Способ лечения мигрени и применение алимемазина тартрата для лечения мигрени
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US8617571B2 (en) 2008-04-03 2013-12-31 Allergan, Inc. Suture line administration technique using botulinum toxin
EP2253343A1 (en) * 2009-05-19 2010-11-24 Fresenius Medical Care Deutschland GmbH Safety insert for extra-corporeal circuits
CN102150196B (zh) 2009-09-08 2013-12-18 松下电器产业株式会社 显示面板装置以及其控制方法
EP2521453B1 (en) 2010-01-08 2016-05-11 Beth Israel Deaconess Medical Center Combinations of vitamin d and a statin for the treatment of migraine headaches
US8940308B2 (en) 2010-03-30 2015-01-27 Allergan, Inc. Methods for treating depression
US20130189354A1 (en) * 2010-10-07 2013-07-25 Trinity Laboratories, Inc., Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
AU2012209274A1 (en) * 2011-01-24 2013-09-12 Anterios, Inc. Nanoparticle compositions, formulations thereof, and uses therefor
US10111938B2 (en) * 2011-03-30 2018-10-30 Allergan, Inc. Injection paradigm for administration of botulinum toxins
BR112014000634A2 (pt) 2011-07-14 2017-02-14 Allergan Inc métodos para tratamento de incontinência associada com atividade sexual
US8491917B1 (en) 2012-03-12 2013-07-23 William J. Bender Treatment of migraine headache with diffusion of toxin in non-muscle related areas of the head
ES2689380T3 (es) 2012-04-03 2018-11-13 Basf Se Composición cosmética capilar que comprende lecitina vegetal
US9005628B2 (en) * 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
DK2948174T3 (da) * 2013-01-28 2019-12-02 Univ New York Fremgangsmåder til behandling under anvendelse af atoksiske neurotoksinderivater
EP2954318B1 (en) 2013-02-06 2023-03-15 Agilent Technologies, Inc. Coupling devices for fluidic conduits and related methods
US20140294923A1 (en) 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2014150899A1 (en) 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
US10933230B2 (en) * 2013-05-06 2021-03-02 Medtronic, Inc. Systems and methods for implanting a medical electrical lead
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP6568099B2 (ja) * 2014-03-21 2019-08-28 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体及びその使用方法
EP3137053B1 (en) 2014-04-30 2020-06-17 Allergan, Inc. Formulations of biologics for intravesical instillation
WO2016040039A1 (en) 2014-09-12 2016-03-17 Allergan, Inc. Methods for treating osteoarthritis pain
JOP20200116A1 (ar) * 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
US11039506B2 (en) 2017-11-30 2021-06-15 International Business Machines Corporation Stove control safety mechanism
WO2020008402A2 (en) * 2018-07-05 2020-01-09 Allergan Pharmaceuticals International Limited Combination therapy with cgrp antagonists and clostridial derivatives

Also Published As

Publication number Publication date
IL222192A (en) 2016-03-31
RU2549981C9 (ru) 2015-07-20
PT2552475T (pt) 2016-08-23
EP2552475A1 (en) 2013-02-06
US20130224180A1 (en) 2013-08-29
JP2013523753A (ja) 2013-06-17
SG184339A1 (en) 2012-11-29
US20100266638A1 (en) 2010-10-21
RU2012145786A (ru) 2014-05-10
HK1179875A1 (zh) 2013-10-11
AU2011211375B2 (en) 2013-09-12
RU2549981C2 (ru) 2015-05-10
US9279001B2 (en) 2016-03-08
JP5700874B2 (ja) 2015-04-15
KR20150090261A (ko) 2015-08-05
PL2552475T3 (pl) 2016-11-30
JP2018090633A (ja) 2018-06-14
US9764011B2 (en) 2017-09-19
CA2794782A1 (en) 2011-10-06
MX2012011227A (es) 2013-01-28
US20130330321A1 (en) 2013-12-12
CA2794782C (en) 2018-11-20
US20120053126A1 (en) 2012-03-01
WO2011123456A1 (en) 2011-10-06
BR112012024920B1 (pt) 2022-04-12
US20200000892A1 (en) 2020-01-02
MX356204B (es) 2018-05-18
US11033610B2 (en) 2021-06-15
EP2735313A1 (en) 2014-05-28
US10406213B2 (en) 2019-09-10
EP2552475B1 (en) 2016-05-18
NZ602983A (en) 2014-10-31
MY156827A (en) 2016-03-31
US20180028624A1 (en) 2018-02-01
US11819541B2 (en) 2023-11-21
US20210299232A1 (en) 2021-09-30
KR20130052731A (ko) 2013-05-23
US8501195B2 (en) 2013-08-06
US20140030248A1 (en) 2014-01-30
JP2016164189A (ja) 2016-09-08
JP5977811B2 (ja) 2016-08-24
SI2552475T1 (sl) 2016-10-28
ES2587437T3 (es) 2016-10-24
EP4140499A1 (en) 2023-03-01
NZ700623A (en) 2016-04-29
US8968747B2 (en) 2015-03-03
IL244154A0 (en) 2016-04-21
HUE030094T2 (en) 2017-04-28
KR101786040B1 (ko) 2017-10-16
JP2015071638A (ja) 2015-04-16
US20160175409A1 (en) 2016-06-23
US8936790B2 (en) 2015-01-20
BR112012024920A2 (pt) 2020-08-25
CA3019983A1 (en) 2011-10-06
IL222192A0 (en) 2012-12-31
CN102917728A (zh) 2013-02-06
AU2011211375A1 (en) 2011-10-06
EP3311831A1 (en) 2018-04-25
DK2552475T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
CY1117910T1 (el) Σχημα δοσολογιας αλλαντικης τοξινης για προφυλαξη εναντι χρονιας ημικρανιας
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
BR112014011404A2 (pt) moléculas de anticorpos com especificidade para o ox40 humano
CY1117440T1 (el) Συτηκτα παραγωγα ιμιδαζολης ως αναστολεις toy ido
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
EA201590655A1 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
MX2009013989A (es) Terapia en combinacion para depresion.
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
EP4079373A4 (en) THERAPEUTIC ULTRASOUND GENERATING DEVICE AND HANDPIECE FOR ULTRASOUND TREATMENT THEREOF
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
UY33219A (es) Cetoenoles cíclicos para terapias
PH12017500392A1 (en) Medical treatments based on anamorelin
BR112018008893A8 (pt) método para tratamento ou amenização de sintomas em um indivíduo com uma doença associada a um nervo craniano em particular, e composição farmacêutica óptica
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2016014701A (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
MX2022007305A (es) Mejoras en la administracion sin aguja.
Wei Harnessing autophagy to potentiate the antitumor effects of the tyrosine kinase inhibitor cabozantinib in prostate cancer cells
TNSN08422A1 (en) Novel low dose pharmaceutical compositions comprising nimesulide, preparation and use thereof